Cover Image
市場調查報告書

全球血液癌症治療藥市場預測

Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

出版商 GBI Research 商品編碼 358648
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
全球血液癌症治療藥市場預測 Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market
出版日期: 2016年04月21日 內容資訊: 英文 147 Pages
簡介

血液癌症治療藥市場,預計從2015年的307億美元,擴大到2022年的701億美元,預計2015年∼2022年以12.5%的年複合成長率成長。

本報告提供血液癌症治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 主要上市產品

  • 概要
  • Rituxan/Mabthera (rituximab) - Roche
  • Gleevec/Glivec (Imatinib) - Novartis
  • Revlimid (lenalidomide) - Celgene
  • Velcade (bortezomib) - Millennium/武田藥品工業/Johnson & Johnson
  • Sprycel (dasatinib) - Bristol-Myers Squibb/大塚製藥
  • Tasigna (nilotinib) - Novartis
  • Pomalyst (pomalidomide) - Celgene
  • Vidaza (azacitidine) - Celgene
  • Kyprolis (carfilzomib) - Onyx/Amgen
  • Adcetris (brentuximab vedotin) - Seattle Genetics/Millennium
  • Imbruvica (ibrutinib) - AbbVie/Johnson & Johnson
  • 結論

第4章 開發平台形勢的評估

  • 概要
  • 開發平台的開發形勢
  • 開發平台的分子標的
  • 臨床實驗情形
  • 結論
  • 複數方案的市場預測
  • 學名藥的普及

第5章 收益預測:各分子標的

第6章 企業分析與地位

  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC407MR

Executive Summary

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin's lymphoma.

Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development.

Scope

The hematological cancers market is characterized by commercially successful therapies.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?
  • How do the leading marketed therapies compare clinically?

The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.

  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?

Hematological cancers clinical trials have an overall attrition rate of 70.3%.

  • What are the failure rates at individual Phases of clinical development?
  • How do leukemia, lymphoma and myeloma compare in terms of clinical trial failure rate?

The hematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%.

  • How much of a role will disease prevalence and new product approvals play in market growth?
  • Will generic competition have a significant impact on the market over the forecast period?

Big pharma hold a notable presence in the market.

  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • What are the drivers of growth for key companies in the market?
  • How dependent are the key companies on this disease cluster for revenue?
  • Which companies rely heavily on this disease cluster for revenue?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in hematological cancers.
  • Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from hematological cancer products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Epidemiology
    • 2.2.1. Leukemia
    • 2.2.2. Lymphoma
    • 2.2.3. Myeloma
  • 2.3. Pathophysiology
    • 2.3.1. Leukemia
    • 2.3.2. Lymphoma
    • 2.3.3. Myeloma
  • 2.4. Symptoms
  • 2.5. Diagnosis
    • 2.5.1. Leukemia
    • 2.5.2. Lymphoma
    • 2.5.3. Myeloma
  • 2.6. Prognosis and Survival
    • 2.6.1. Survival
  • 2.7. Treatment
    • 2.7.1. Surgery and Radiation Therapy
    • 2.7.2. Stem Cell Transplantation
    • 2.7.3. Pharmacological Therapies

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Rituxan/Mabthera (rituximab) - Roche
  • 3.3. Gleevec/Glivec (Imatinib) - Novartis
  • 3.4. Revlimid (lenalidomide) - Celgene
  • 3.5. Velcade (bortezomib) - Millennium/Takeda/Johnson & Johnson
  • 3.6. Sprycel (dasatinib) - Bristol-Myers Squibb/Otsuka Pharmaceutical
  • 3.7. Tasigna (nilotinib) - Novartis
  • 3.8. Pomalyst (pomalidomide) - Celgene
  • 3.9. Vidaza (azacitidine) - Celgene
  • 3.10. Kyprolis (carfilzomib) - Onyx/Amgen
  • 3.11. Adcetris (brentuximab vedotin) - Seattle Genetics/Millennium
  • 3.12. Imbruvica (ibrutinib) - AbbVie/Johnson & Johnson
  • 3.13. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion
  • 4.5. Multi-scenario Market Forecast to 2023
    • 4.5.1. Overall Market Size
  • 4.6. Generic Penetration

5. Revenue Forecast by Molecular Target

  • 5.1. Cancer Immunotherapies/Tumor-Associated Antigen
  • 5.2. Signal Transduction
  • 5.3. Receptor Tyrosine Kinases and Ligands
  • 5.4. Revenue and Market Share Analysis by Company
    • 5.4.1. Celgene - Will Revenue Loss Associated with Vidaza, Thalomid and Istodax Impact Celgene's Position as Market Leader?
    • 5.4.2. Roche - Will the Patent Expiry of Rituxan Significantly Diminish Revenues?
    • 5.4.3. AbbVie/Pharmacyclics - AbbVie Acquiring Pharmacyclics will Drive AbbVie's Sales Growth
    • 5.4.4. Novartis - Large and Growing Product Portfolio to Maintain Revenue Growth
    • 5.4.5. Johnson & Johnson - Imbruvica and Velcade Partnerships to be Predominant Contributors to Revenue Growth
  • 5.5. Assessment of Key Pipeline Products
    • 5.5.1. Venetoclax (ABT-199) - AbbVie/Roche
    • 5.5.2. KTE-C19-Kite Pharma
    • 5.5.3. Selinexor (KPT-330) - Karyopharm Therapeutics
    • 5.5.4. Polatuzumab Vedotin (RG-7596) - Roche
    • 5.5.5. Tisagenlecleucel-T (CTL-019) - Novartis
    • 5.5.6. Midostaurin (PKC-412) - Novartis
    • 5.5.7. Conclusion

6. Company Analysis and Positioning

  • 6.1. Company Landscape
  • 6.2. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deal by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Molecular Target and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. Bibliography
  • 8.2. Table of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Secondary Research
    • 8.5.2. Market Size and Revenue Forecasts
    • 8.5.3. Pipeline Analysis
    • 8.5.4. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016
  • Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016
  • Table 3: Hematological Cancers Therapeutics Market, Global, Multiple Myeloma, Prognostic Factors, 2016
  • Table 4: Hematological Cancers Therapeutics Market, Global, Commonly Used Chemo-Regimens, 2016
  • Table 5: Hematological Cancers Therapeutics Market, Global, Approved Indications for Rituxan, 2016
  • Table 6: Hematological Cancers Therapeutics Market, Global, Approved Indications for Gleevec, 2016
  • Table 7: Hematological Cancers Therapeutics Market, Global, Approved Indications for Revlimid, 2016
  • Table 8: Hematological Cancers Therapeutics Market, Global, Approved Indications for Velcade, 2016
  • Table 9: Hematological Cancers Therapeutics Market, Global, Approved Indications for Sprycel, 2016
  • Table 10: Hematological Cancers Therapeutics Market, Global, Approved Indications for Tasigna, 2016
  • Table 11: Hematological Cancers Therapeutics Market, Global, Approved Indications for Pomalyst, 2016
  • Table 12: Hematological Cancers Therapeutics Market, Global, Approved Indications for Vidaza, 2016
  • Table 13: Hematological Cancers Therapeutics Market, Global, Approved Indications for Kyprolis, 2016
  • Table 14: Hematological Cancers Therapeutics Market, Global, Approved Indications for Adcetris, 2016
  • Table 15: Hematological Cancers Therapeutics Market, Global, Approved Indications for Imbruvica, 2016
  • Table 16: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Table 17: Hematological Cancers Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016
  • Table 18: Hematological Cancers Therapeutics Market, Global, Forecast Revenue by Company, 2016
  • Table 19: Hematological Cancers Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Table 20: Hematological Cancers Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
  • Table 21: Hematological Cancers Therapeutics Market, Global, Pipeline Products in Clinical Development, 2016

List of Figures

  • Figure 1: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Leukemia, 2015-2022
  • Figure 2: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Lymphoma, 2015-2022
  • Figure 3: Hematological Cancers Therapeutics Market, Global, Epidemiology Patterns for Myeloma, 2015-2022
  • Figure 4: Hematological Cancers Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2016
  • Figure 5: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Rituxan ($bn), 2006-2022
  • Figure 6: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Gleevec ($bn), 2006-2021
  • Figure 7: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Revlimid ($bn), 2006-2022
  • Figure 8: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Velcade ($bn), 2006-2022
  • Figure 9: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Sprycel ($bn), 2006-2022
  • Figure 10: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Tasigna ($bn), 2008-2022
  • Figure 11: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2022
  • Figure 12: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Vidaza ($bn), 2008-2022
  • Figure 13: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Kyprolis ($bn), 2012-2022
  • Figure 14: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Adcetris ($bn), 2011-2022
  • Figure 15: Hematological Cancers Therapeutics Market, Global, Annual Revenue for Imbruvica ($bn), 2014-2022
  • Figure 16: Hematological Cancers Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 17: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 18: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Stage of Development, 2016
  • Figure 19: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecule Type, 2016
  • Figure 20: Hematological Cancers Therapeutics Market, Global, Pipeline for Hematological Cancers by Molecular Target, 2016
  • Figure 21: Hematological Cancers Therapeutics Market, Global, Pipeline for Key Hematological Cancers by Molecular Target, 2016
  • Figure 22: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 23: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 24: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 25: Hematological Cancers Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 26: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
  • Figure 27: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 28: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 29: Hematological Cancers Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 30: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
  • Figure 31: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 32: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 33: Hematological Cancers Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 34: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
  • Figure 35: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 36: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 37: Hematological Cancers Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 38: Hematological Cancers Therapeutics Market, Global, Market Size ($bn), 2015-2022
  • Figure 39: Hematological Cancers Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
  • Figure 40: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Cancer Immunotherapies/Tumor Associated Antigen ($bn), 2015-2022
  • Figure 41: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction ($bn), 2015-2022
  • Figure 42: Hematological Cancers Therapeutics Market, Global, Annual Revenue Forecast for Receptor Tyrosine Kinase and Ligands ($bn), 2015-2022
  • Figure 43: Hematological Cancers Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 44: Hematological Cancers Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
  • Figure 45: Hematological Cancers Therapeutics Market, Global, Revenue by Product Type, 2015-2022
  • Figure 46: Hematological Cancers Therapeutics Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
  • Figure 47: Hematological Cancers Therapeutics Market, Global, Roche Annual Revenue ($bn), 2015-2022
  • Figure 48: Hematological Cancers Therapeutics Market, Global, AbbVie/Pharmacyclics Annual Revenue ($bn), 2015-2022
  • Figure 49: Hematological Cancers Therapeutics Market, Global, Novartis Annual Revenue ($bn), 2015-2022
  • Figure 50: Hematological Cancers Therapeutics Market, Global, Johnson & Johnson Annual Revenue ($bn), 2015-2022
  • Figure 51: Hematological Cancers Therapeutics Market, Global, Revenue for Venetoclax ($bn), 2015-2022
  • Figure 52: Hematological Cancers Therapeutics Market, Global, Revenue for KTE-C19 ($bn), 2015-2022
  • Figure 53: Hematological Cancers Therapeutics Market, Global, Revenue for Selinexor ($bn), 2015-2022
  • Figure 54: Hematological Cancers Therapeutics Market, Global, Revenue for Polatuzumab Vedotin ($bn), 2015-2022
  • Figure 55: Hematological Cancers Therapeutics Market, Global, Revenue for Tisagenlecleucel-T ($bn), 2015-2022
  • Figure 56: Hematological Cancers Therapeutics Market, Global, Revenue for Midostaurin ($m), 2015-2022
  • Figure 57: Hematological Cancers Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 58: Hematological Cancers Therapeutics Market, Global, Companies by Type, 2016
  • Figure 59: Hematological Cancers Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Hematological Cancers Specialization, 2016
  • Figure 60: Hematological Cancers Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Hematological Cancers, 2015-2022
  • Figure 61: Hematological Cancers Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Hematological Cancers, Top Five Companies ($bn), 2015-2022
  • Figure 62: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
  • Figure 63: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Indication and Value, 2006-2016
  • Figure 64: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
  • Figure 65: Hematological Cancers Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
  • Figure 66: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
  • Figure 67: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
  • Figure 68: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
  • Figure 69: Hematological Cancers Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016
Back to Top